| Literature DB >> 29480797 |
Shahram Mobaraki1, Mohammad Aghazadeh2, Mohammad Hossein Soroush Barhaghi2, Mohammad Yousef Memar3, Hamid Reza Goli4, Pourya Gholizadeh5, Hossein Samadi Kafil1.
Abstract
BACKGROUND: The presence of Class 1, 2 and 3 integrons in clinical isolates of Pseudomonas aeruginosa with multi-drug resistance phenotype has rendered the organism as a new concern.Entities:
Year: 2018 PMID: 29480797 PMCID: PMC5825915 DOI: 10.1051/bmdcn/2018080102
Source DB: PubMed Journal: Biomedicine (Taipei) ISSN: 2211-8020
List of primers were used for the PCR amplification and sequencing of integrons in the present study.
| Target region | Primer sequence (5́ → 3́) | Size of product | Annealing Temperature | References |
|---|---|---|---|---|
| TCATGGCTTGTTATGACTGT | 600 bp | 57̊C | 26 | |
| GATGCCATCGCAAGTACGAG | 750 bp | 57̊C | 27 | |
| GCCTCCGGCAGCGACTTTCAG | 650 bp | 59̊C | 28 | |
bp = base pair, F = forward sequence, R = reverse sequence.
The relationship between the presence of integrons and resistance to antibiotics in clinical isolates of Pseudomonas aeruginosa in the present study.
| All isolates (n = 200) | Integron positives (n = 55) | Integron negatives (n = 145) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Antibiotics | R | I | S | R | I | S | R | I | S | |
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||
| Amikacin | 110 | 9 | 81 | 34 | 2 | 19 | 79 | 3 | 63 | NS |
| (55) | (4.5) | (40.5) | (61.8) | (3.6) | (34.5) | (54.4) | (2) | (43.4) | ||
| Cefepime | 125 | 0 | 75 | 36 | 0 | 19 | 89 | 0 | 56 | NS |
| (62.5) | (37.5) | (65.4) | (34.5) | (61.3) | (38.6) | |||||
| Ceftazidime | 113 | 0 | 67 | 40 | 0 | 15 | 93 | 0 | 52 | NS |
| (66.5) | (33.5) | (72.7) | (27.2) | (64.1) | (33.8) | |||||
| Tobramycin | 115 | 0 | 85 | 26 | 0 | 29 | 86 | 0 | 59 | NS |
| (57.5) | (42.5) | (47.2) | (52.7) | (59.3) | (40.6) | |||||
| Gentamicin | 124 | 0 | 76 | 39 | 0 | 16 | 85 | 0 | 60 | NS |
| (62) | (38) | (70.9) | (29) | (58.9) | (41.3) | |||||
| Imipenem | 93 | 12 | 95 | 25 | 3 | 17 | 73 | 5 | 67 | NS |
| (46.5) | (6) | (47.5) | (45.4) | (5.4) | (30.9) | (50.3) | (3.4) | (46.2) | ||
| Colistin | 6 | 0 | 194 | 2 | 0 | 53 | 4 | 0 | 141 | NS |
| (3) | (97) | (3.6) | (96.3) | (2.7) | (97.2) | |||||
| Ciprofloxacin | 125 | 0 | 75 | 33 | 0 | 22 | 88 | 0 | 57 | NS |
| (62.5) | (37.5) | (60) | (40) | (60.6) | (39.3) | |||||
| Amoxicillinclavulanate | 121 | 0 | 79 | 33 | 0 | 22 | 86 | 0 | 59 | NS |
| (60.5) | (39.5) | (60) | (40) | (59.3) | (40.6) | |||||
| Cefotaxime | 149 | 3 | 48 | 39 | 1 | 15 | 109 | 2 | 34 | NS |
| (74.5) | (1.5) | (24) | (70.9) | (1.8) | (27.2) | (75.1) | (1.3) | (23.4) | ||
| Ceftazidimeclavulanate | 110 | 0 | 90 | 33 | 0 | 22 | 77 | 0 | 68 | NS |
| (55) | (45) | (60) | (40) | (53.1) | (46.8) | |||||
R: resistant. I: intermediate. S: susceptible. NS: not statistically significant.
Statistical analysis was done by Chi-square method using SPSS software. All other statistical analysis were done by descriptive methods.
Gene cassettes in the Class I integrons in clinical isolates of Pseudomonas aeruginosa.
| Length of variable region (s) (bp) | Gene cassette (s) | No. of isolates (%) | The name of hospital (s) |
|---|---|---|---|
| 750 | 3 (5.4%) | I,I,I | |
| 1200 | 4 (7%) | I,I,I,I | |
| 1200 | 13 (24%) | I,I,I,I,S,S,I,S,S,I,I,I,I | |
| 1250 | 20 (36%) | I,I,I,I,I,S,I,I,I,I,I,I,I,S,S,S,I,I,I,I | |
| 1500 | 2 (3.5%) | I,I | |
| 1700 | 13 (24%) | I,I,I,I I,I,I,I,I,I,I,I,I,I | |
| Total |
* I: Imam, S: Sina. C: Kodakan.
Gene cassettes in the Class II integrogens structure by PCR method in clinical isolates of Pseudomonas aeruginosa.
| Length of variable region (s) (bp) | Gene cassette (s) | No. of isolates (%) | The name of hospital (s) |
|---|---|---|---|
| 500 | 15 (30%) | I,I,I,I,I,S,S,S,I,I,S,I,I,I,P | |
| 600 | Hypothetical gene cassette | 15(30%) | I,I,I,I,I,I,I,S,S,P,P,S,S,I,I |
| Total |
*I: Imam. S: Sina. C: Kodakan.
Gene cassettes in the Class III integrogens structure by PCR method in clinical isolates of Pseudomonas aeruginosa.
| Length of variable region (s) (bp) | Gene cassette (s) | No. of isolates (%) | The name of hospital (s) |
|---|---|---|---|
| 400 | 30(59%) | I,I,I,I,I,I,I,S,S,S,I,I,I,I,I,I,I,S,I,S,I,I,I,I,P,I,I,I,I,I | |
| 600 | Hypothetical gene cassette | 21(41%) | I,I,I,S,I,I,S,I,I,I,I,S,I,I,I,P,S,P,P,S,P |
| Total |
* I: Imam. S: Sina. C: Kodakan.